Virax Biolabs Group Limited (VRAX)
Virax Biolabs Group is a holding company incorporated with no material operations of its own.
We conduct our substantial operations in the United Kingdom and Hong Kong with operating subsidiaries in Singapore, China and British Virgin Islands and have been operating since 2013.
We are a global innovative biotechnology group that primarily engages in sales, distribution and marketing of diagnostics test kits and med-tech and Personal Protective Equipment products for the prevention, detection, diagnosis and risk management of viral diseases with a particular interest in the field of immunology.
Our mission is to minimize the risks of viruses throughout the world via our products offerings. Our product portfolio includes: (i) diagnostics test kits sold through our “ViraxClear” brand; (ii) med-tech and PPE products sold through our “ViraxCare” brand; and (iii) sourced brands of third party suppliers, independent of our own brands.
We also expect to launch an upcoming brand “Virax Immune”, with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against major global viral diseases.
|IPO Date||Jul 21, 2022|
30 Broadwick Street
London W1F 8LX
|Phone||44 20 7788 7414|
|Fiscal Year||April - March|
|Reporting Currency||US Dollars|
|James Foster||Chairman and Chief Executive Officer|
|Jason D. Davis||Chief Financial Officer|
|Cameron Lee Shaw||Chief Operating Officer and Director|
|Mark James Ternouth||Chief Technical Officer|
|Dr. Tomasz Evan George||Chief Scientific Officer|